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Background: The epidemiology of paediatric bloodstream infection (BSI) in Sub-Saharan Africa is poorly documented
with limited data on hospital-acquired sepsis, impact of HIV infection, BSI trends and antimicrobial resistance.
Methods: We retrospectively reviewed paediatric BSI (0–14 years) at Tygerberg Children’s Hospital between 1 January
2008 and 31 December 2013 (excluding neonatal wards). Laboratory and hospital data were used to determine BSI
rates, blood culture contamination, pathogen profile, patient demographics, antimicrobial resistance and factors
associated with mortality. Fluconazole resistant Candida species, methicillin-resistant Staphylococcus aureus
(MRSA), multi-drug resistant Acinetobacter baumannii and extended-spectrum beta-lactamase (ESBL) producing
Enterobacteriaceae were classified as antimicrobial resistant pathogens.
Results: Of 17001 blood cultures over 6 years, 935 cultures isolated 979 pathogens (5.5% yield; 95% CI 5.3-5.7%).
Contamination rates were high (6.6%, 95% CI 6.4-6.8%), increasing over time (p = 0.003). Discrete BSI episodes were
identified (n = 864) with median patient age of 7.5 months, male predominance (57%) and 13% HIV prevalence. BSI
rates declined significantly over time (4.6–3.1, overall rate 3.5 per 1000 patient days; 95% CI 3.3–3.7; Chi square for trend
p = 0.02). Gram negative pathogens predominated (60% vs 33% Gram positives and 7% fungal); Klebsiella pneumoniae
(154; 17%), Staphylococcus aureus (131; 14%) and Escherichia coli (97; 11%) were most prevalent. Crude BSI mortality was
20% (176/864); HIV infection, fungal, Gram negative and hospital-acquired sepsis were significantly associated with
mortality on multivariate analysis. Hospital-acquired BSI was common (404/864; 47%). Overall antimicrobial resistance
rates were high (70% in hospital vs 25% in community-acquired infections; p < 0.0001); hospital-acquired infection,
infancy, HIV-infection and Gram negative sepsis were associated with resistance. S. pneumoniae BSI declined significantly
over time (58/465 [12.5%] to 33/399 [8.3%]; p =0.04).
Conclusion: Although BSI rates declined over time, children with BSI had high mortality and pathogens exhibited
substantial antimicrobial resistance in both community and hospital-acquired infections. Blood culture sampling
technique and local options for empiric antimicrobial therapy require re-evaluation.
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The epidemiology of paediatric bloodstream infection
(BSI) in Africa is poorly documented. A meta-analysis of
prospective studies of community-acquired BSI [1] iden-
tified 22 eligible studies (four in Southern Africa) [2-5],
where non-typhoidal Salmonella, E. coli, S. aureus and S.
pneumoniae infection predominated. Despite published* Correspondence: dramowski@sun.ac.za
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children [1-9] data on hospital-acquired BSI are ex-
tremely limited [10,11]. It is estimated that healthcare-
associated BSI may be responsible for 25000 deaths in
African children annually [12]. Overall, incidence rates
of healthcare-associated infection in developing countries
are thought to be at least double that of high-income
settings [13]. Further research on the epidemiology of
hospital-acquired BSI in African children is needed to
quantify the burden and better understand contributory
factors.tral. This is an Open Access article distributed under the terms of the Creative
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children are expected, given increasing access to HIV pre-
vention programmes, paediatric antiretroviral therapy and
inclusion of pneumococcal conjugate vaccine (PCV) in
the immunisation schedule [14,15]. In light of globally
increasing antimicrobial resistance [12], regional anti-
microbial resistance prevalence and the efficacy of
empiric antibiotic therapy for paediatric BSI in Sub-
Saharan Africa also require evaluation. Descriptions of
increasing prevalence of Enterobacteriaceae BSI isolates
producing extended-spectrum beta-lactamases (ESBL)
are concerning given the limited availability of appropriate
antibiotics in many African countries [16].
The difficulties in obtaining paediatric blood culture
specimens and the increased yield with higher volume
blood inoculum are well described [8]. Of concern in
our region are two recent audits [17,18] reporting low
pathogen yields and high blood culture contamination
rates (exceeding accepted rates of < 3%) [19]. We exam-
ined trends in paediatric BSI epidemiology over six years
at a single academic institution, determining rates of
bacteraemia, blood culture yield and contamination,
BSI-associated mortality and prevalence of antimicrobial
resistance. We also investigated the association between
bacteraemia, antimicrobial resistance and HIV infection.
Methods
Setting
We retrospectively reviewed paediatric BSI at Tygerberg
Children’s Hospital (TCH) in Cape Town, South Africa
between 1 January 2008 and 31 December 2013 (excluding
neonatal wards). The TCH admits sick infants and children
(0–14 years) requiring general (70%) or specialised (30%)
paediatric care (haematology/oncology, nephrology, gastro-
enterology, infectious diseases, cardiology, neurology, pul-
monology, paediatric surgery, endocrinology) to one of
six wards (153 beds; 85% occupancy rate in 2013). The
10-bedded medical/surgical paediatric intensive care unit
(PICU) has an 89% occupancy rate (2013). Critically-ill
children requiring ventilation or inotropic support are
preferentially managed in the PICU but also on the wards
when PICU is full.
The antenatal HIV prevalence in the Western Cape
Province was 16.9% in 2012 (versus 29.5% nationally)
[20]. Among children aged 2–14 years, HIV prevalence
in the Western Cape Province was 0.7% in 2012 (versus
2.4% nationally) [21]. Antiretroviral therapy has been
available since 2004, including prevention of mother-to-
child HIV infection transmission, with transmission rates
of 3.9% in 2010 [22]. HIV testing with informed consent
is performed if the child’s status is unknown, using an
HIV PCR if < 18 months and HIV Elisa if > 18 months.
If the HIV status is already known, no laboratory sample
is submitted. Thus for this study only HIV tests taken atthe time of hospitalisation, or taken at prior hospital
visits were accessible.
Immunisation coverage in the Cape Metropolitan area
in 2011/12 was 87.5% among the population < 1 year of
age (including BCG, polio, diphtheria/tetanus/pertussis,
hepatitis B and measles vaccines; rotavirus was introduced
in 2009) [23]. Haemophilus influenzae serotype B (Hib)
conjugate vaccine was introduced in 1995 and PCV for S.
pneumoniae in 2009 (7-valent) and 2011 (13- valent) [15].
Investigation and management of BSI
Blood cultures are obtained from all children with sus-
pected sepsis or severe infection with a focal site (e.g.
pneumonia, cellulitis). Empiric antibiotic therapy for
community-acquired sepsis depends on the presumed
site of infection, but usually includes either ceftriaxone
or ampicillin and gentamicin. Empiric treatment of
hospital-acquired infection usually includes meropenem,
or ertapenem if Pseudomonas aeruginosa is considered
unlikely and meningitis is excluded. Vancomycin is
added if MRSA is considered a likely pathogen e.g. with
suspected central line sepsis or soft tissue infection in
hospital.
Blood culture sampling and analysis
A single blood culture sample (one bottle) is submitted
from most patients, unless infective endocarditis is sus-
pected. Local guidelines recommend inoculation of at
least 2 mL of blood into paediatric blood culture bottles,
however for older children, larger blood inoculums of
5 – 10 ml are encouraged. Blood cultures are taken at
the discretion of attending clinicians and transferred to
the on-site National Health Laboratory Service (NHLS)
microbiology laboratory for processing in an automated
system. Prior to April 2011 the Bactec system (Becton
Dickinson, New Jersey, United States) was used; and
thereafter the BacT/Alert system (BioMerieux, Marcy l′
Etoile, France), in line with NHLS policy. For both sys-
tems, paediatric-specific culture bottles were used (Becton
Dickinson BACTEC Peds Plus/F and thereafter BacT/
ALERT® PF bottles). Both contain specialized media that
accommodate small-volume samples (≤3 mL of blood)
and resin for antibiotic neutralization. If bacterial growth
is detected in the bottles, a Gram stain is performed, the
sample sub-cultured onto appropriate media based on the
Gram stain and incubated overnight. Further identifica-
tion and antimicrobial susceptibility testing of clinically
significant isolates is performed with the automated Vitek
II system (BioMerieux, Marcy l’Etoile, France), using
annually published Clinical and Laboratory Standards
Institute (CLSI) breakpoints [24]. Pneumococcal isolates
were considered non-susceptible to penicillin at minimum
inhibitory concentrations (MICs) ≥0.12 mg/L using the
meningitis breakpoints for parenteral penicillin [24].
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All positive blood cultures from the paediatric wards
over the six year study period were extracted from the
computerised laboratory database; demographic data was
obtained from the laboratory and hospital admissions
database. BSI rates, blood culture contamination, patho-
gen profile, patient demographics and factors associated
with antimicrobial resistance and BSI mortality were de-
termined. Organisms were categorised using the United
States Centers for Disease Control (US CDC) list of path-
ogens and contaminants; common commensals defined
by the CDC include diphtheroids [Corynebacterium spp.
not C. diphtheriae], Bacillus spp. [not B. anthracis], Pro-
pionibacterium spp., coagulase-negative staphylococci
[including S. epidermidis], viridans group streptococci,
Aerococcus spp., and Micrococcus spp [25]. Positive blood
cultures obtained < 72 hours after admission were classi-
fied as community-acquired sepsis. Those obtained >72
hours after admission were considered hospital-acquired
sepsis. All positive blood cultures isolating the same patho-
gen within 14 days were considered a single episode of BSI.
Fluconazole resistant Candida species, methicillin-resistant
Staphylococcus aureus (MRSA), multi-drug resistant
Acinetobacter baumannii (resistant to at least 3 classes
of antimicrobials) and extended spectrum B-lactamase
(ESBL)-producing Enterobacteriaceae were classified as
antimicrobial resistant pathogens using proposed standard
definitions [26].
Statistical analysis
The BSI rate was calculated by dividing the total number
of BSI episodes by the total inpatient days accumulated
during the 6 year period. The pathogen and contamin-
ation rates were calculated by dividing the number of
blood cultures yielding pathogens and contaminants re-
spectively by the total number of blood culture requested.
Continuous and categorical variables were compared using
student t tests and Chi square analysis respectively. A
Chi square test for linear trend was used to assess
change in rates over the study period. To determine fac-
tors associated with mortality from BSI and antimicrobial
resistance, binary logistic regression analyses were per-
formed. A p-value below 0.05 was considered statistically
significant. Stata Statistical Software version 13.0 IC
(College Station, TX: StataCorp LP) was used.
Ethical approval
Ethical approval and waiver of individual informed consent
was obtained from the Human Health Research Ethics
committee of Stellenbosch University (S13/09/171).
Results
For 63209 children hospitalized over the study period,
17001 blood culture specimens were submitted; 1 bloodculture per 3.7 admissions or 68.6 specimens/1000 pa-
tient days. From 935 culture–positive specimens, 979
BSI pathogens were isolated (5.5% yield; 95% CI 5.3-
5.7%). Blood culture contamination rates were high
(1123 contaminated blood cultures from 17001 blood
culture specimens submitted [6.6%]; 95% CI 6.4-6.8%),
increasing over time (p = 0.003) (Figure 1). Coagulase-
negative staphylococci (CoNS) were the most commonly
isolated contaminant (650/1123; 57.9%), followed by non-
pathogenic streptococci (75/1123; 6.7%), Bacillus species
(74/1123; 6.6%), Micrococcus species (63/1123; 5.6%) and
diphtheroids (61/1123; 5.4%).
Of 864 discrete BSI episodes, 818 (94.7%) were mono-
microbial infections and 46 (5.3%) were polymicrobial
(42 with 2 pathogens; 4 with 3 pathogens). The overall
BSI rate was 3.5 per 1000 patient days (95% CI 3.3–3.7).
A significant decline in the BSI rate from 4.6 in 2008 to
3.1 in 2013 (Chi square for trend p = 0.02; Figure 1) was
noted despite substantial increases in hospitalizations
(7537 to 11201 [49%]) and number of blood cultures
(7816 vs 9185 [17%]) submitted between 2008 and 2013.
The median age of patients with BSI episodes was
7.5 months with male predominance (57.4%) and 13.4%
HIV prevalence (however the test positivity rate was 20.6%
[116/564], when children of unknown HIV [n = 299] sta-
tus were excluded) (Table 1). Most patients (679; 78.6%)
had blood cultures submitted from general paediatric
wards i.e. were not yet in the PICU. Nearly half of all BSI
episodes were hospital-acquired (404; 46.8%), with a me-
dian hospital stay of 17 days (IQR = 8 – 33.5 days) before
onset of BSI. The overall rate of hospital-acquired BSI was
1.63 episodes per 1000 patient days (404/247969; 95% CI
1.49 – 1.78) and declined between 2008–2010 and 2011–
2013 (from 1.79 to 1.49/1000 patient days; p = 0.06). The
risk of developing hospital-acquired BSI during hospital-
isation was 6.4 per 1000 admissions (95% CI 5.8 – 7.0).
Gram negative organisms predominated (60.2%) followed
by Gram positives (32.4%) and fungi (7.4%). Klebsiella
pneumoniae (154; 17%), Staphylococcus aureus (131; 14%)
and Escherichia coli (97; 11%) were most prevalent
(Table 2). The profile and proportional representation
of pathogens varied markedly by location (ward vs
PICU) and by place of onset. Gram positive pathogens
were more prevalent in community-acquired isolates
and Gram negative and fungal pathogens in hospital-
acquired sepsis. The spectrum and ranking of BSI path-
ogens among children known to be HIV infected was
similar to that of HIV uninfected patients, except for S.
pneumoniae which was more common in HIV infected
children (20/116 [17.2%] vs 30/448 [6.7%]; p < 0.001).
While H. influenzae BSI episodes increased between
2008–2010 and 2011–2013 (7/465 [1.5%] to 15/399
[3.8%]; p = 0.05), the proportion of H. influenzae sero-
type B isolates remained similar (3/7 [42.9%] vs 5/15
Figure 1 Trends in bloodstream infection, pathogen and contamination rates (2008–2013). BSI rates (blue) declined significantly (from 4.6
to 3.1 per 1000 patient days; Chi square for trend p = 0.02). Blood culture contamination rates (grey) were high (1123/17001 [6.6%]; 95% CI 6.4-6.8%)
exceeding pathogen yield (orange) and increased over time (p = 0.003).
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significantly (58/465 [12.5%] to 33/399 [8.3%]) (p = 0.04).
Pneumococci as a percentage of all Gram positive patho-
gens declined from a pre-vaccine high of 43.5% (27/62) in
2008 to 13.1% (8/61) in 2013 [p < 0.001]. The proportion
of pneumococcal BSI due to vaccine-serotypes (account-
ing for PCV7 and PCV13) did not decrease significantly
over the two time periods, despite PCV-13 giving broader
coverage (20/68 [29.4%] vs 6/23 [26%], p = 0.99). The
proportion of pneumococcal BSI exhibiting penicillin-
resistance remained unchanged between 2008–2010
and 2011–2013, (18/58 [31%] vs 10/33 [30.3%]; p = 1.0).
Overall crude BSI mortality was 20.4% (176/864);
patients with hospital-acquired BSI experienced higher
mortality than community-acquired BSI (25% [101/404]
vs 16.3% [75/460]; p = 0.002). The pathogen associated
with the highest BSI mortality was Acinetobacter spp
(p = 0.03) at 38% (30/78), followed by Candida species
(31%; 20/65) and E coli BSI (24%; 23/97). HIV, fungi,
Gram negative organisms and hospital-acquired sepsis
were significantly associated with BSI mortality on
multivariate analysis (Table 3).Prevalence of antimicrobial resistance was assessed
among a subset of pathogens, focussing on fluconazole
resistant Candida species and four bacterial pathogens:
MRSA, multi-drug resistant Acinetobacter baumannii and
ESBL-producing E coli and K. pneumoniae (Figure 2). No
carbapenem resistant Enterobacteriaceae (CRE) or vanco-
mycin resistant Enterococci (VRE) were isolated. For the
four selected bacterial pathogens, antimicrobial resistance
prevalence among community isolates was 25% compared
with 70% among hospital-acquired isolates (p < 0.001). For
A. baumannii and MRSA, resistance rates were signifi-
cantly higher among hospital-acquired isolates, whereas E.
coli and K. pneumoniae isolates had similar prevalence of
ESBLs among hospital- and community-acquired isolates.
Among the 65 Candida species, all 21 C. albicans isolates
were fluconazole susceptible, while 22 of the 44 (50%)
non-albicans Candida species were fluconazole resistant.
The prevalence of antimicrobial resistance did not differ
significantly between 2008–2010 and 2011–2013 for the
selected pathogens [Chi square for trend p = 0.24 and
p = 0.14 respectively]. Factors associated with anti-
microbial resistance on multivariate analysis included
Table 1 Demographic profile of paediatric patients with bloodstream infection
Variable Number (n) Percentage (%) Age Age Age p-value
<1 yr 1 - 5 yrs 5 - 14 yrs
(n; %) (n; %) (n; %)
Laboratory confirmed-BSI episodes* 864 100% 506 (58.6) 206 (23.8) 152 (17.6) -
Median age (months) 7.5 IQR 3.2 18.2 96 -
2.9-23.8
Male 496 57.4 298 (58.9) 111 (53.9) 89 (58.5) 0.41
HIV status
- Positive 116 13.4 68 (13) 31 (15) 17 (11)
- Negative 448 52 271 (54) 101 (49) 76 (50) 0.57
- Unknown 299 34.6 167 (33) 74 (36) 59 (39)
Onset of BSI#
- Community-acquired 460 53.2 244 (53) 133 (29) 83 (18) <0.001
- Hospital-acquired 404 46.8 262 (65) 73 (18) 69 (17)
Ward at BSI diagnosis
- Intensive care 185 21.4 140 (28) 33 (16) 12 (8) <0.001
- General ward 679 78.6 366 (72) 173 (84) 140 (92)
BSI outcome
- Died 176 20.4 109 (22) 45 (22) 22 (14) 0.13
- Survived 688 79.6 397 (78) 161 (78) 130 (86)
Crude mortality rate by age - 20.4 21.5 21.8 14.5 -
*BSI episodes: blood culture sampling episodes that yielded a pathogen, excluding blood cultures that isolated the same organism within 14 days of the original
sampling episode; IQR = interquartile range; #CA-BSI = BC submitted within first 72 hours of admission; HA-BSI = BC submitted > 72 hours after admission. Continuous
and categorical variables were compared using student t tests and Chi square analysis respectively; p < 0.05 was considered statistically significant.
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Gram negative sepsis (Table 4).
Susceptibility to different combinations of empiric
antimicrobial therapy for hospital-acquired BSI was
determined for all BSI isolates from 2012 and 2013
(Table 5). The combination of meropenem and amikacin
was the most active against both ward and ICU BSI iso-
lates, based on the in-vitro susceptibility test results
(overall 82/133; 83.6% of isolates susceptible to one or
both agents).
Discussion
In keeping with previous studies from Africa, gram neg-
atives predominated in our study. E. coli and Klebsiella
spp. were the most prevalent Enterobacteriaceae. Non-
typhoidal salmonellae, a prominent BSI pathogen in
malaria-endemic regions [27], was uncommon in our
study. S. pneumoniae (the most common isolate in
community-acquired BSI in African children [1]), was
also prominent in our cohort. In addition, the profile of
gram positive isolates changed significantly over time
owing to reduced frequency of S. pneumoniae detection.
The proportion of vaccine-serotype pneumococcal BSI
isolates remained stable over time suggesting that thedramatic decline in pneumococcal sepsis rates is not
solely attributable to vaccine. However, a study of inva-
sive pneumococcal disease in South Africa did demon-
strate a substantial reduction of 89% in disease caused
by PCV7 serotypes in children <2 years old [28]. Other
factors such as increasing antiretroviral uptake and de-
creasing HIV prevalence probably contributed. Fungi
(especially hospital-acquired) and gram negatives were
significantly associated with BSI mortality, as in other
African studies [6,10,11].
The burden of paediatric BSI was concentrated among
infants (58.6% of the cohort). Young age was not associ-
ated with mortality from BSI but was significantly asso-
ciated with antimicrobial resistant pathogens. Overall
BSI mortality in our cohort (20.4%) was higher than that
reported for high income settings (11 - 14%) [29,30], but
lower than other African settings (27 – 38%) [6,10,11].
Access to intensive care was not reported for the other
African BSI studies and likely contributed to the lower
case fatality in our cohort, although PICU facilities at
our institution are very limited (only 1 in 5 patients was
admitted in PICU at BSI diagnosis).
As previously reported [10], HIV-infected children
were at increased risk for BSI-associated mortality and
Table 2 Microbiological profile of paediatric bloodstream infection episodes (n = 864)
BSI episodes n % Total pathogens isolated from 864 BSI episodes*
Monomicrobial 818 94.7 914
Polymicrobial
- 2 pathogens 42 4.8
- 3 pathogens 4 0.5
Gram negatives Organism n = 550 % of Gram negatives Organism rank*
Enterobacteriaceae K. pneumoniae 154 28% 1
E. coli 97 18% 3
E. cloacae 30 5% 7
S. marcescens 19 3% 10
Salmonella spp 18 3%
(non-typhi)
Klebsiella spp 12 2%
Other (9 different genera) 30 5%
Total 360 65%
Non-fermenting Gram negative bacilli A. baumannii 78 14% 5
P. aeruginosa 20 4% 9
Acinetobacter spp 16 3%
S. paucimobilis 9 2%
Other (9 different genera) 20 4%
Total 143 26%
Other Gram negative organisms H. influenzae 23 4% 8
N. meningitidis 11 2%
Other (6 different genera) 13 3%
Total 47 9%
Gram positives Organism n = 296 % of Gram positives Organism rank*
Staphlylococci Staphylococcus aureus 131 44% 2
Streptococci Streptococcus pneumoniae 91 31% 4
Group B Streptococcus 19 6% 10
Enterococci Enterococcus spp 46 16% 6
Other Gram positive organisms Other (4 different genera) 9 3%
Fungi Organism n = 68 % of Fungi Organism rank*
Candida spp Candida albicans 21 31% 9
Candida tropicalis 12 18%
Candida parapsilosis 9 13%
Candida glabrata 3 4%
Candida krusei 2 3%
All other candida spp 18 27%
Other fungi Aspergillus spp, 1 4%
Trichosporon spp, 1
unidentified yeast 1
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Table 2 Microbiological profile of paediatric bloodstream infection episodes (n = 864) (Continued)
BSI pathogens (n = 914) by type and place of infection onset for 864 BSI episodes
Community-acquired (CA-BSI) pathogens Hospital-acquired (HA-BSI) pathogens
n = 477 n = 437
CA-BSI ward pathogens# n = 433 % HA-BSI ward pathogens# n = 275 %
- Staphylococcus aureus 90 21 - Klebsiella pneumoniae 86 31
- Streptococcus pneumoniae 81 19 - Candida spp 28 10
- Escherichia coli 67 15 - Acinetobacter baumanni 26 10
- Other 195 45 - Other 135 49
CA-BSI ICU pathogens# n = 44 % HA-BSI ICU pathogens# n = 162 %
- Escherichia coli 9 21 - Acinetobacter baumanni 42 26
- Klebsiella pneumoniae 7 16 - Klebsiella pneumoniae 33 20
- Staphylococcus aureus 5 11 - Candida spp 22 14
- Other 23 52 - Other 65 40
*Total pathogens isolated from 864 BSI episodes = 914 pathogens (818 monomicrobial + polymicrobial 42 × 2 isolates + 4 × 3 isolates) #CA-BSI = BC submitted
within first 72 hours of admission; HA-BSI = BC submitted > 72 hours after admission; ICU = intensive care unit; *Organism rank reported for the top ten
isolates only.
Table 3 Bloodstream infection-associated mortality
BSI-associated mortality Number (n) Percentage (%) p-value
Total BSI-associated deaths 176 100 -
Male 97 55.1 0.49
Median age (months) IQR 7.2 IQR 3–14.7 -
HIV status
- Positive 34 19.3
- Negative 87 49.4 0.03
- Unknown 55 31.3
Onset of BSI#
- Community-acquired 75/460 16.3 0.002
- Hospital-acquired 101/404 25
Factors associated with mortality from BSI
Variable assessed Univariate analysis
(p-value)
Multivariate analysis
(p-value)
Odds ratio 95% CI
Length of stay prior to BSI onset <0.001 0.11 - -
Age category 0.13 0.44 - -
Gender 0.49 0.32 - -
HIV status (positive) 0.03 0.02 1.74 1.1 - 2.8
Year of BSI 0.89 0.78 - -
Place of BSI onset (hospital-acquired) 0.002 0.04 1.43 1.1 - 2.0
Type of BSI pathogen 0.001 0.03
- Fungal 2.10 1.1 – 4.2
- Gram negative 1.88 1.2 – 2.9
Mono- vs poly-microbial BSI 0.72 0.6 - -
ICU vs general ward at BSI onset <0.001 0.001 2.93 1.9 – 4.4
Antimicrobial resistance 0.06 0.83 - -
BSI = bloodstream infection; ICU = intensive care unit; #CA-BSI = BC submitted within first 72 hours of admission; HA-BSI = BC submitted > 72 hours after admission.
To determine factors associated with mortality from BSI and antimicrobial resistance, binary logistic regression analyses were performed. A p-value below 0.05 was
considered statistically significant.
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MRSA MDR A. baumannii ESBL K.
pneumoniae
ESBL E. coli Pooled resistance
for 4 pathogens
Community BSI 15.3 25 75.7 11.7 25
Hospital BSI 65 72.4 78.3 21.7 65.8
p-value 0.0001 0.01 0.82 0.3 0.0001
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Antimicrobial resistance in selected BSI pathogens (%)
Figure 2 Antimicrobial resistance (%) in selected paediatric bloodstream infection pathogens. Methicillin-resistant Staphylococcus aureus
(MRSA), multi-drug resistant Acinetobacter baumannii (resistant to at least 3 classes of antimicrobials) and extended spectrum B-lactamase (ESBL)-producing
Enterobacteriaceae were classified as antimicrobial resistant pathogens using proposed definitions for resistance [26]. Community- vs hospital-acquired
blood culture isolates of these pathogens were compared for frequency of antimicrobial resistance, individually and in a combined analysis.
BSI = bloodstream infection; MDR = multi-drug resistant (according to published criteria) [24]; MRSA = methicillin resistant Staphylococcus
aureus; ESBL = extended spectrum beta-lactamase producer; Community BSI = community-acquired BSI; Hospital BSI = hospital-acquired
BSI; Pooled resistance for four bacterial pathogens = MRSA, MDR A. baumanni, ESBL K. pneumoniae and ESBL E.coli.
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Bacterial colonisation is a risk factor for later invasive in-
fection with high rates of colonisation with antimicrobial
resistant pathogens described among HIV-infected chil-
dren in Cape Town [31]. It was not possible (given the
study design) to compare the relative risk for BSI among
HIV-infected versus HIV-uninfected children or theTable 4 Factors associated with antimicrobial resistance
Variable assessed Univariate analysis
(p-value)
Length of stay prior to BSI onset <0.001
Age category (infants) <0.001
Gender 0.8
HIV status (positive) <0.001
Year of BSI 0.4
Place of BSI onset (hospital-acquired) <0.001
Type of BSI pathogen
- Gram negative <0.001
Mono- vs poly-microbial BSI 0.18
ICU vs general ward at BSI onset <0.001
BSI = bloodstream infection; ICU = intensive care unit; Hospital-acquired BSI = BC sub
antimicrobial resistance, binary logistic regression analyses were performed. A p-vaeffect of antiretroviral therapy. A prospective study is
underway at our institution to determine the relative risk
for hospital-acquired infection (including BSI) among
HIV-infected children.
Hospital-acquired BSI was common (nearly half of all BSI
episodes), more prevalent among infants and significantly
associated with mortality. The profile of hospital-acquiredMultivariate analysis
(p-value)
Odds ratio 95% CI
0.53 - -
0.003 1.92 1.2 – 3.1
0.92 - -
<0.001 2.64 1.7 – 4.2
0.19 - -
<0.001 3.68 2.7 – 5.1
<0.001 1.99 1.4 – 2.9
0.84 - -
0.06 - -
mitted > 72 hours after admission. To determine factors associated with
lue below 0.05 was considered statistically significant.
Table 5 Coverage achieved for hospital-acquired bloodstream infections with empiric antimicrobial regimens (2012–2013)*
Antibiotic susceptibility OVERALL
n = 159
WARD
n = 92
PICU
n = 67
Ward vs
PICU
SUSCEPTIBLE
Number (n) Percentage (%) Number (n) Percentage (%) Number (n) Percentage (%) p-value
piperacillin tazobactam + amikacin 122 76.7 71 77.2 50 74.6 0.7
ertapenem 110 69.1 71 77.2 40 59.7 0.02
meropenem 112 70.4 70 76 42 62.7 0.08
meropenem + amikacin 133 83.6 82 89.1 51 76 0.03
meropenem + vancomycin 119 74.8 73 79.3 46 68.7 0.14
PICU=paediatric intensive care unit; *only pathogens isolated in 2012 and 2013 were included in this analysis in order to determine recent antimicrobial resistance patterns.
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BSI with Klebsiella, Acinetobacter and Candida species
predominating. In keeping with the only prospective study
of hospital-acquired bacteraemia in African children, Aci-
netobacter sepsis had the highest case fatality rates in our
cohort. The rate of hospital-acquired BSI in our study
exceeded the rate of nosocomial bacteraemia in rural Kenya
(1.63 versus 1.0 episodes per 1000 patient days), however
our cohort had a substantially higher HIV prevalence
(13.4% vs 2%) [11]. Unsurprisingly, hospital isolates exhib-
ited significantly greater antimicrobial resistance. Unlike
the Tanzanian cohort [10], antimicrobial resistance was not
associated with BSI mortality, possibly due to our use of
carbapenems for empiric treatment of hospital-acquired
sepsis.
A worrying observation is the high rate of antimicrobial
resistance among community-acquired pathogens, espe-
cially. E.coli and Klebsiella spp. Inappropriate empiric
antimicrobial therapy (due to ESBL-producing and multi-
resistant pathogens) predicted death in the Tanzanian
cohort (OR 12.9) [10]. It is possible that pre-hospital
antibiotic administration in our cohort may have falsely
elevated antimicrobial resistance rates for community-
acquired pathogens, by decreasing the frequency of isola-
tion of susceptible pathogens. However our data are in
keeping with pooled laboratory data (2010–2012) from
public sector hospitals in South Africa demonstrating
ESBL-carriage in 68% of 2774 K. pneumoniae BSI isolates
[32]. Ongoing surveillance of antimicrobial resistance in
community BSI (and monitoring of clinical outcomes
among children given ineffective antibiotic therapy) is
needed to determine if antibiotic guidelines need revision.
Among hospital-acquired BSI in the last two years of
the study period, isolates exhibited highest susceptibility
(83.6%) to meropenem plus amikacin, not currently our
recommended empiric regimen. A prospective review,
which includes clinical data on response to therapy is
urgently needed to inform our guidelines for treatment
of hospital-acquired sepsis. However, given the need for
antimicrobial stewardship (and restriction of carbapenem
use), it is also important to assess the efficacy of narrower-spectrum regimens (such as piperacillin-tazobactam and
amikacin).
Our review of temporal trends in paediatric BSI epi-
demiology identified targets for quality improvement.
Although not unique to our setting, blood culture
contamination rates were high (double the international
norm [19]) and increased over time (exceeding the rate
of pathogen isolation). The annual pathogen yield de-
clined significantly over time and in 2013 (4.9%; 95% CI
3.9 – 5.2) was substantially lower than blood culture
yields from a systematic review in Africa (8.2%; 95% CI
7.9 – 8.4) [1]. There are several explanations for these
findings including poor aseptic technique during speci-
men collection with failure to isolate pathogens because
of overgrowth by c ontaminants, low sensitivity of
paediatric blood cultures and sub-optimal blood vol-
umes from children [8]. Prior administration of antibi-
otics also contributes to low blood culture yield: local
management guidelines [33] recommend that critically-
ill children referred in from primary care receive a sin-
gle dose of intramuscular ceftriaxone prior to transfer.
Between the two study time periods, BSI rates declined
significantly despite a substantial increase in hospitalization
(measured by increased inpatient days) and despite an
increase in actual numbers of blood culture specimens
submitted. We suspect that improvements in PMTCT
programmes, paediatric antiretroviral coverage and PCV
introduction between 2008 and 2013 are partly respon-
sible. However, declining pathogen yields (as described
above) may also have artificially reduced BSI rates.
This study has several limitations, most importantly
the possibility that some healthcare-associated BSI (re-
admission within 30 days of hospital discharge) may
have been misclassified as community-acquired, owing
to the retrospective study design. We chose 72 hours as
a more conservative cut-off for hospital-acquired bacter-
aemia (many authorities use 48 hours) to avoid possibly
including some community bacteraemias as hospital-
acquired. The time of blood culture collection and the
time of developing symptoms/signs of infection (as op-
posed to blood culture collection) were not routinely
Dramowski et al. BMC Pediatrics  (2015) 15:33 Page 10 of 11available. The use of 72 hours as a cut-off, may have slightly
underestimated the nosocomial bacteraemia rate. We were
unable to evaluate the appropriateness of empiric therapy
for community-acquired BSI, as the locally recommended
treatment regimen depends on the child’s clinical presenta-
tion. Lack of standardized patient selection or technique
for blood culture, lack of comprehensive clinical data or
information on recent antibiotic use and/or hospitalisation
are also limitations. Many patients had unknown HIV
status, but were likely tested at a different facility.
Although BSI rates declined over time, we could not
determine which factors and practices contributed to
this trend. In addition, the BSI rates may have been
significantly underestimated owing to pre-hospital anti-
biotic administration and inadequate blood volumes
submitted for culture. We believe that change in the la-
boratory culturing system and average volume of blood
inoculum are less likely explanations for the decline in
BSI rate, since the blood culture contamination rate
increased significantly over time. However, differences in
pathogen yield between the two systems have been de-
scribed, and the impact of a different blood culture system
on the BSI rate cannot be completely discounted [34-36].
Given the relatively good resources and care at our in-
stitution (including an infection prevention and control
service and PICU facilities), these findings may be more
generalizable to better-resourced African settings. Rec-
ommendations for local practice arising from this study
include urgent review of paediatric blood culture prac-
tice (emphasizing aseptic technique and adequate blood
inoculum) and review of empiric antibiotic therapy for
both community and hospital-acquired BSI.
Conclusions
Children with BSI experienced high mortality, particularly
for hospital-acquired infection. S. pneumoniae BSI declined
after introduction of PCV and increasing antiretroviral
coverage. Pathogens (both community- and hospital-
acquired) exhibited substantial antimicrobial resistance.
Although BSI rates declined, blood culture contamin-
ation rates increased; blood culture sampling technique
and local options for empiric antimicrobial therapy re-
quire re-evaluation.
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